Proud of @paslombardi for his efforts in addressing unmet needs in 2L therapy for HCC

LEVIATHAN publication Get expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for #HCC 📺 from Prof. David Pinato (@DJPinato) 🤝 Programme endorsed by @EuropeLiver, @BlueFaeryLiver, @GlobalLiver & @ESDO_tweets View/download the infographic:

STRIDE preserves efficacy outside HIMALAYA - 🕵️‍♂️the first and largest cohort of D+T treated patients now on @JHEP_Reports / DT-Real @CiroCelsa https://t.co/GJZZNcvW0K

How to treat patients with #HCC and portal vein thrombosis @ILCAnews @ImperialSandC

Super proud of Zhongguo Zhou @ImperialSandC for the outstanding @ILCAnews award 🥇

We work on small but incremental benefit in #CCA

⭐️Intermediate stage HCC⭐️ ➡️how to integrate LRT/IO; do we need for all,what is tace eligible ➡️which LRT-immunogenicity evident ➡️patient factors imp ➡️curing select bclc b with effective tx ➡️endpoint considerations imp in trial design 🎉fabulous overview @DJPinato #esmo2025

#ESMO25 💥 Great presentation of #mRNA4359 and Pembrolizumab 🗣️ @DJPinato 👥 Melanoma r/R PD-1/PD-L1 ✔️ ORR 24% ⬆️ ORR 64% if PDL1 >1% ✅ Translational data ☣️ 10% =>G3 @OncoAlert @myESMO @_SEOM @ASCO

LEVIATHAN demonstrates not all TKIs are equally effective after Atezolizumab + Bevacizumab in #HCC - new 2L benchmarks thanks to @paslombardi at @ImperialSandC https://t.co/LxZMAEF16v

Today @imperialcollege confers upon me the title of full Professor of Experimental Cancer Therapeutics & Medical Oncology. I owe this to more people I can count but dedicate it to my patients past and future, with the promise that enthusiasm to improve cancer care won’t stop here

Meta-analysis showed atezolizumab+bevacizumab most favorably balances OS and QoL for HCC. The combo reduces deterioration in global health, abdominal swelling, jaundice, pain vs sorafenib. @DJPinato https://t.co/TLeNomKDAP #HCC #Immunotherapy

Grateful to @ASCOPost @ASCO for the highlight 🙂 QoL is an important measure of success @CiroCelsa @cabibbo78 @imperialcollege @UniAvogadro

How can QoL help us making decisions around systemic therapy for #HCC ? @imperialcollege @UniAvogadro https://t.co/rnXmMwoOMR

Quality of life matters in #HCC! Read our last network meta-analysis now online on @JAMAOnc @DJPinato @cabibbo78 @A_DAlessioMD @FulgenziClaudia @BeStef33 @gfmanfredi @paslombardi

Very proud of @paslombardi for his 🥇 Best Poster Prize at @myESMO #ESMOGI25 @imperialcollege @ImperialSandC

I will soon be deactivating my @X profile If you would like to stay in touch professionally and personally follow me on BlueSky @bluesky https://t.co/a5UFGNIt8m

Wonderful news - @ConquerCancerFd has chosen our work on neoadj ICI in HCC for the 2025 ASCO GI Merit Award🏅Pathological or radiological response as best RFS predictor? See you at my poster next Friday in San Francisco ! @DJPinato @ImperialSandC @ASCO

Patient advocate sharing patients’ preferences, goals, and values (not necessarily in this order) about (but not only) subcutaneous vs iv immunotherapy in #HCC and #NSCLC at #ESMOAsia24 in #Singapore @myESMO @DJPinato @tohhc

@DJPinato discussing systemic therapeutic options for patients with #HCC at #ESMOAsia24 in #Singapore @myESMO

I will soon be abandoning @X I don’t want my content to go to the profit of those who don’t care for the benefit of humanity https://t.co/a5UFGNJ0XU